BaumannJ.M., BisazS., FelixR., FleischM., GanzU., RussellR.G.: The role of inhibitors and other factors in the pathogenesis of recurrent calcium containing renal stones. Clin. Sci. (Mol. Med.), 53; 141–148 (1977).
2.
CaudarellaR., RizzoliE., BerveglieriF., MartelliG., MalavoltaN.: Calcolosi calcica idiopatica: ruolo dei glicosaminoglicani (GAGs) e dei solfati (SO4). 28° Congr. Soc. Ital. Nefrol., Torino, 3–6 giugno 1987.
3.
CaudarellaR., RizzoliE., BerveglieriF., MartelliG., MalavoltaN.: Studio della escrezione urinaria dei glicosaminoglicani nei soggetti normali e nei pazienti con calcolosi calcica idiopatica. Giorn. Ital. Metab. Min. Elettr., 3; 55–61 (1989).
4.
CoeF.L., MargolisH.D., DeutschL.H., StraussA.L.: Urinary macromolecular crystal growth inhibition in calcium nephrolithiasis. Mineral electrol. Metabolism., 3; 268–275 (1980).
5.
NakagawaN., AbramV., KezdyF., KaiserE.T., CoeF.R.: Purification and charactarization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J. Biol. Chem., 258; 12594–12600 (1983).
6.
RyallR.L., DarrochJ.H., MarshallV.R.: The evaluation of risk factors in male stone formers attending a general hospital out patients clinic. Brit. J. Urol, 56; 116–121 (1984).
7.
SallisJ.D., BichlerK.H., KornS., HaubmannA.: Urinary glycosaminoglycan excretion in patients with urolithiasis. In: Smith, Robertson, Finlayson (eds): Urolithiasis.Clinical and basic research, 619–622 (1981).
8.
SamuellC.T.: A study of glycosaminoglycan excretion in normal and stone forming subjects using a modified cetylpyridinium chloride technique. Clin. Chim. Acta, 117; 63–73 (1981).
